Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
|
|
IO Biotech, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/21/2023 |
3
| Kurma Partners (10% Owner) has filed a Form 3 on IO Biotech, Inc. |
| 08/16/2023 |
SC 13G
| Stonepine Capital Management, LLC reports a 5.8% stake in IO Biotech, Inc. |
| 08/15/2023 |
4
| Hunter Heidi (Director) has filed a Form 4 on IO Biotech, Inc.|
Txns:
| Granted 64,238 options to buy
@ $1.83, valued at
$117.6k
|
|
| 08/15/2023 |
3
| Hunter Heidi (Director) has filed a Form 3 on IO Biotech, Inc. |
| 08/15/2023 |
SC 13G/A
| HBM Healthcare Investments Ltd. reports a 8.2% stake in IO Biotech, Inc. |
| 08/14/2023 |
SC 13G/A
| HBM Healthcare Investments Ltd. reports a 6.1% stake in IO Biotech, Inc. |
| 08/14/2023 |
SC 13D/A
| Lundbeckfond Invest A/S reports a 29.6% stake in IO Biotech, Inc. |
| 08/11/2023 |
4
| Elling Christian E (10% Owner) has filed a Form 4 on IO Biotech, Inc.|
Txns:
| Granted 7,901,234 shares
@ $1.9, valued at
$15M
Granted 7,901,234 warrants
@ $2.47, valued at
$19.5M
|
|
| 08/11/2023 |
4
| Lundbeckfond Invest A/S (10% Owner) has filed a Form 4 on IO Biotech, Inc.|
Txns:
| Granted 7,901,234 shares
@ $1.9, valued at
$15M
Granted 7,901,234 warrants
@ $2.47, valued at
$19.5M
|
|
| 08/11/2023 |
SC 13D/A
| Novo Holdings A/S reports a 12% stake in IO Biotech, Inc. |
| 08/11/2023 |
4
| Novo Holdings A/S (10% Owner) has filed a Form 4 on IO Biotech, Inc.|
Txns:
| Bought 2,469,135 shares
@ $2.025, valued at
$5M
Bought 2,469,135 warrants
@ $2.47, valued at
$6.1M
|
|
| 08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/11/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
4
| Vivo Capital IX, LLC (10% Owner) has filed a Form 4 on IO Biotech, Inc.|
Txns:
| Bought 3,157,894 shares
@ $1.9, valued at
$6M
Bought 3,157,894 warrants
@ $2.47, valued at
$7.8M
|
|
| 08/09/2023 |
4
| Zocca Mai-Britt (CEO) has filed a Form 4 on IO Biotech, Inc.|
Txns:
| Granted 37,037 shares
@ $1.9, valued at
$70.4k
Granted 37,037 warrants
@ $2.47, valued at
$91.5k
|
|
| 08/09/2023 |
4
| Sullivan Amy (CFO) has filed a Form 4 on IO Biotech, Inc.|
Txns:
| Granted 49,382 shares
@ $1.9, valued at
$93.8k
Granted 49,382 warrants
@ $2.47, valued at
$122k
|
|
| 08/09/2023 |
4
| Smith Devin Whittemore (General Counsel) has filed a Form 4 on IO Biotech, Inc.|
Txns:
| Granted 4,938 shares
@ $1.9, valued at
$9.4k
Granted 4,938 warrants
@ $2.47, valued at
$12.2k
|
|
| 08/07/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Form of Warrant",
"Securities Purchase Agreement, by and among the Company and the Purchasers",
"Registration Rights Agreement, by and among the Company and the Purchasers",
"IO Biotech, Inc. Announces $75 Million Private Placement Financing • Offering includes participation from both new and existing healthcare-dedicated investors. • Proceeds extend the company's cash runway into the fourth quarter of 2025 NEW YORK, August 7, 2023 - IO Biotech, Inc. , a clinical biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced that it has entered into a definitive securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $75 million, before deducting offering expenses. The private placement includes participation from new and existing investors, including Lundbeckfonden BioCapital; Kurma Growth Opportunities Fund; Vivo Capital; Armisti...",
"Corporate Presentation" |
|
| 07/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/19/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 07/18/2023 |
8-K
| Quarterly results |
| 06/09/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 04/26/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/26/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/26/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/20/2023 |
8-K
| Quarterly results |
| 04/14/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/22/2023 |
4
| Al-Hajj Muhammad (Chief Scientific Officer) has filed a Form 4 on IO Biotech, Inc.|
Txns:
| Granted 120,000 options to buy
@ $1.98, valued at
$237.6k
|
|
| 03/22/2023 |
4
| Zocca Mai-Britt (CEO) has filed a Form 4 on IO Biotech, Inc.|
Txns:
| Granted 500,000 options to buy
@ $1.98, valued at
$990k
|
|
| 03/22/2023 |
4
| Sullivan Amy (CFO) has filed a Form 4 on IO Biotech, Inc.|
Txns:
| Granted 55,000 options to buy
@ $1.98, valued at
$108.9k
|
|
| 03/22/2023 |
4
| Burkavage Brian (Chief Accounting Officer) has filed a Form 4 on IO Biotech, Inc.|
Txns:
| Granted 50,000 options to buy
@ $1.98, valued at
$99k
|
|
| 03/22/2023 |
4
| Ehrnrooth Eva (Chief Medical Officer) has filed a Form 4 on IO Biotech, Inc.|
Txns:
| Granted 120,000 options to buy
@ $1.98, valued at
$237.6k
|
|
|
|
|